Guarda Bluejay Nuda: Foto e Video Aggiornati

What's going on with Bluejay Diagnostics shares on Wednesday?

Bluejay Sport Review: A Vintage-Looking Ebike For City And Off-Road Adventures

Bluejay Announces Receipt of PRIME Designation from European Medicines Agency (EMA) for BJT-778 for the Treatment of Chronic Hepatitis Delta Virus Infection

Bluejay Therapeutics raises $41 million in Series B round to drive clinical trials in chronic hepatitis

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Inside The Growing Popularity of Bluejay e-bikes

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

BlueJay is a music playing, editing, and recording software for Windows

Bluejay Diagnostics Completes Private Placement to Extend Runway

Bluejay Mining pulls demerger plan, aims to raise $6 million

Bluejay Mining goes solo at Finland project as JV with Rio Tinto ends

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bluejay Mining plc (LON:JAY) is largely controlled by institutional shareholders who own 49% of the company

Bluejay Mining enters final permitting stages for massive ilmenite project in Greenland

Bluejay Capital Partners Recapitalizes Quality Life Science Logistics & Transportation

Mirum to Acquire Bluejay and Its Late-Stage HDV Candidate for Up to US$820M

Why is Bluejay Diagnostics stock soaring Tuesday?

Husker and Bluejay, Jacobsen and Traudt put in-state rivalry on hold for the next generation

Bluejay Diagnostics Shareholders Approve Stock Plan and Flexibility

Bluejay Nears Completion of Pivotal SYMON-II Sepsis Trial

Bluejay Diagnostics, Inc. Completes 90 Subjects in Multicenter Clinical Study Addressing Rapid IL-6 Test for COVID-19 Patients in Critical Care

Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results

Bluejay Diagnostics Forms U.S. Manufacturing Partnership for Symphony

Bluejay Therapeutics Received Regulatory Clearance to Initiate Clinical Studies of BJT-778 for Treatment of Chronic Hepatitis B and Chronic Hepatitis D

Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook

Sponsored Content: The Spotlight – BlueJay

Bluejay Diagnostics announces 1-for-4 reverse stock split

Mirum beckons Bluejay and its phase 3-stage hepatitis drug for $620M

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Bluejay Diagnostics Announces Reverse Stock Split